GLP-1 Injections for Weight Loss: What You Need to Know Before Starting
Short answer: GLP-1 injections are FDA-approved weekly medications that help qualifying adults lose roughly 12–20% of their body weight by reducing appetite and slowing digestion. Before starting in late 2026, the three things to know are: which option fits you (injection vs. oral pill, semaglutide vs. tirzepatide vs. orforglipron), whether you qualify by BMI, and exactly what the Medicare GLP-1 Bridge program — now active — covers at $50 a month. A licensed provider can confirm what’s safe and appropriate for your health.
At Omnia Telehealth, our licensed providers manage weight loss treatment virtually — eligibility, prescription, dosing, and follow-up — so you can start safely from home. Here’s what to understand first.
What are GLP-1 injections and how do they work?
GLP-1 (glucagon-like peptide-1) is a natural hormone that regulates appetite, insulin, and blood sugar. GLP-1 receptor agonists mimic that hormone, which is why they’re so effective for weight management. They work by:
- Reducing hunger and overall calorie intake
- Slowing gastric emptying, so you feel full longer
- Improving insulin sensitivity and blood sugar control
- Supporting steady, sustained weight loss over months
Originally developed for type 2 diabetes, semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are now FDA-approved for chronic weight management in qualifying patients. A third option — orforglipron (Foundayo) — joined them in April 2026 as the first truly flexible oral GLP-1 (no food or water restrictions). They’re typically given as a once-weekly injection or daily pill, with the dose increased gradually to limit side effects.
How much weight can you actually lose on a GLP-1?
The results in clinical trials are substantial, which is why demand has stayed high. The amount depends on the specific medication.
| Medication | Route | Average Weight Loss | Key Trial |
|---|---|---|---|
| Wegovy (semaglutide) | Weekly injection | ~15% at 68 weeks | STEP 1 (NEJM, 2021) |
| Zepbound (tirzepatide) | Weekly injection | ~20% at 72 weeks | SURMOUNT-1 (NEJM, 2022) |
| Foundayo (orforglipron) | Daily oral pill | ~12.4% at 72 weeks | ATTAIN-2 (Lancet, 2026) |
| Oral Wegovy (semaglutide) | Daily oral pill | ~15% (similar to injection) | OASIS 1 (Lancet, 2023) |
A 2026 head-to-head trial published in The Lancet found that orforglipron delivered superior blood sugar control and comparable weight loss to oral semaglutide in patients with type 2 diabetes, with the added convenience of no timing or food restrictions. Real-world results vary, and weight loss is fastest when medication is paired with nutrition and activity changes.
Who qualifies for GLP-1 therapy?
GLP-1 weight loss treatment is generally appropriate for:
- Adults with a BMI ≥ 30, or
- Adults with a BMI ≥ 27 plus at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol, or sleep apnea.
GLP-1s are not recommended if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), and they’re avoided in pregnancy. This is exactly what a provider screens for during your intake. Through Omnia’s virtual platform, a licensed provider reviews your history, confirms eligibility, and tailors your plan.
What are my GLP-1 options in 2026 — including the new pills?
The menu has expanded considerably and continues to grow. Here’s the current landscape as of Q4 2026:
| Option | Type | Key advantage |
|---|---|---|
| Wegovy (semaglutide) | Brand injectable | Most studied; ~15% average loss |
| Zepbound (tirzepatide) | Brand injectable | Strongest average loss (~20%); dual GIP/GLP-1 |
| Oral Wegovy (semaglutide) | Daily pill (take in AM, empty stomach) | Injection-free; same molecule as Wegovy |
| Foundayo (orforglipron) | Daily pill (take anytime, no food restriction) | Most flexible oral; Lancet head-to-head data |
Foundayo’s key practical advantage over oral Wegovy: it can be taken any time of day without food or water restrictions. Oral Wegovy must be taken in the morning on an empty stomach, which is an inconvenience some people find unsustainable. Your provider will help weigh that flexibility against cost, formulary coverage, and your health history.
What about compounded semaglutide — is it still an option?
This is the biggest regulatory change of recent years. During the shortage years, compounded semaglutide was a cheap, widely available substitute. That era has largely ended: the FDA declared the semaglutide and tirzepatide shortages resolved and finalized rules in 2026 removing both drugs from the list compounders may produce at scale.
For most people, the safer and clearer path in 2026 is an FDA-approved brand medication, especially now that pricing programs have narrowed the cost gap substantially. We cover the details — and what to do if you’re currently on a compounded GLP-1 — in our dedicated explainer: Is Compounded Semaglutide Still Legal in 2026?
How much do GLP-1 medications cost in 2026? (Medicare Bridge is now live)
Cost was the main reason people sought compounded versions, and that gap is closing fast:
- TrumpRx pricing offers certain brand GLP-1s at roughly $245/month for eligible enrollees.
- The Medicare GLP-1 Bridge Program launched July 1, 2026 and runs through December 31, 2027. Eligible Medicare Part D enrollees pay $50/month for covered medications, including Foundayo, Wegovy (pills and injections), and Zepbound KwikPens.
Important Medicare Bridge eligibility note: The $50 copay program is available to enrollees who don’t already have GLP-1 coverage through their Part D plan. Enrollees who have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease receive GLP-1 coverage through a separate Part D pathway and are excluded from the Bridge. Your provider can confirm which route applies to you.
Looking further ahead: CMS plans to launch BALANCE in January 2027, a five-year demonstration program allowing Part D plans to negotiate and broadly cover GLP-1 weight loss drugs — expected to expand access substantially beyond the Bridge.
What side effects should I expect?
Most people tolerate GLP-1 medications well, especially when the dose is increased slowly. The most common side effects are gastrointestinal:
- Nausea or vomiting (most common; usually improves after first weeks)
- Constipation or diarrhea
- Fatigue
- Injection-site reactions (for injectables)
Two additional effects that frequently come up:
- Hair shedding (telogen effluvium): Some people experience temporary hair loss around months 2–4, usually from rapid weight loss rather than the medication itself. It typically self-resolves. See our full guide: GLP-1 Hair Loss: Why It Happens and How to Treat It.
- Muscle loss: GLP-1s can cause loss of lean muscle alongside fat, particularly at higher doses. The current evidence supports pairing GLP-1 therapy with adequate protein intake (≥1.2 g/kg of body weight) and resistance training. See our protocol: Don’t Lose Muscle on a GLP-1.
Frequently Asked Questions
How soon will I see results from GLP-1 injections?
Most people notice reduced appetite within the first few weeks, with meaningful weight loss typically beginning around weeks 4 to 8 and continuing for months as the dose increases.
Can I get a GLP-1 prescription online?
Yes. A virtual consultation with a licensed provider, a prescription if medically appropriate, and a pharmacy delivery can all happen from home. Legitimate telehealth always includes a real medical intake and provider review — not just an automated questionnaire.
Are GLP-1 injections safe for long-term use?
They’re FDA-approved for long-term weight management and have been studied extensively in multi-year trials. Because obesity is a chronic condition, many people stay on therapy long-term under provider supervision.
Does the Medicare GLP-1 Bridge cover injections and pills?
The Bridge covers Wegovy (both injection and oral pill), Foundayo (orforglipron pill), and Zepbound KwikPens. Zepbound single-use pens and vials are not included in the Bridge. Coverage runs July 1, 2026 – December 31, 2027, at a $50/month copay for eligible Part D enrollees.
What happens if I stop taking a GLP-1?
Weight regain is common after stopping because the medication’s appetite effects end. Most people regain some weight within the first few months. Maintaining nutrition, activity, and provider support helps protect your results — your provider can discuss tapering and maintenance strategies well before you stop. Our full guide: How to Keep the Weight Off After You Stop a GLP-1.
Start your GLP-1 evaluation with a licensed provider
GLP-1 medications are among the most effective non-surgical weight loss tools available, and in late 2026 you have more legal, FDA-approved options than ever — injectable or pill, brand or Medicare-covered. The right next step is a conversation with a licensed clinician who can confirm what’s safe for you, verify your Medicare eligibility, and build a plan around your goals.
Ready to begin? Start an online weight-loss consultation with Omnia Telehealth and let a licensed provider guide you from your first dose through ongoing follow-up.
This article is for general educational purposes and is not medical advice. Always consult a licensed healthcare provider about your individual situation. Individual results and eligibility vary.